James N. Topper - 03 Jun 2025 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: PHAT
Reported as of: 03 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2025, 16:56:34 UTC
Prior SEC filing: 23 May 2025
Next SEC filing: 18 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Steven Basta, Attorney-in-Fact for James Topper

Key filing fact

James N. Topper filed Form 4 for Phathom Pharmaceuticals, Inc. (PHAT) on 05 Jun 2025.

Key facts

This page summarizes James N. Topper's Form 4 filing for Phathom Pharmaceuticals, Inc. (PHAT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2025, 16:56.

Change

Previous filing in this sequence was filed on 23 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001341382 Primary reporting owner

Topper James N

Relationship: Director, 10%+ Owner
Address: C/O PHATHOM PHARMACEUTICALS, INC., 100 CAMPUS DRIVE, SUITE 102, FLORHAM PARK,
Signature: /s/ Steven Basta, Attorney-in-Fact for James Topper
Signature date: 05 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PHAT transaction

Common Stock

Award

Transaction value: $0
Shares: +10,500
Change %: +33%
Price: $0.000000
Shares after: 42,596
Date: 03 Jun 2025
Ownership: Direct
Footnotes: F1

PHAT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 59,403
Date: 03 Jun 2025
Ownership: By Frazier Life Sciences X, L.P.
Footnotes: F2

PHAT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 5,827,415
Date: 03 Jun 2025
Ownership: By Frazier Life Sciences IX, L.P.
Footnotes: F3

PHAT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1
Date: 03 Jun 2025
Ownership: By FHMLS IX, L.L.C.
Footnotes: F4

PHAT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,912
Date: 03 Jun 2025
Ownership: By Topper Group III LLC
Footnotes: F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PHAT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +17,500
Change %
Price: $0.000000
Shares after: 17,500
Date: 03 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,500
Exercise price: $4.95
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The Restricted Stock Units ("RSUs") were granted on June 3, 2025, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

Footnote F2

The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Footnote F3

The shares reported herein are held of record by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. and FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. The Reporting Person is one of two managing members of FHMLS IX, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Footnote F4

The shares reported herein are held of record by FHMLS IX, L.L.C. The Reporting Person is one of two managing members of FHMLS IX, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Footnote F5

The Reporting Person is a manager of Topper Group III LLC and has voting and investment power of the securities held by Topper Group III LLC.

Footnote F6

The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the firstanniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vestingdate.